Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji H. | - |
dc.contributor.author | Yu, Sang K. | - |
dc.contributor.author | Seo, Yeon S. | - |
dc.contributor.author | Yim, Hyung J. | - |
dc.contributor.author | Yeon, Jong E. | - |
dc.contributor.author | Park, Jong J. | - |
dc.contributor.author | Kim, Jae S. | - |
dc.contributor.author | Bak, Young T. | - |
dc.contributor.author | Lee, Chang H. | - |
dc.contributor.author | Byun, Kwan S. | - |
dc.date.available | 2020-11-03T11:49:56Z | - |
dc.date.issued | 2007-08 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.issn | 1440-1746 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/17817 | - |
dc.description.abstract | Background and Aim: A small proportion of chronic hepatitis B patients have persistently detectable serum hepatitis B virus (HBV) DNA despite lamivudine therapy. The incidence and clinical outcomes of patients who persistently have detectable serum HBV-DNA during lamivudine therapy was investigated. Method: We enrolled 221 chronic hepatitis B patients who underwent lamivudine therapy for more than 6 months. Among them, 180 were HBeAg positive. Serum HBV-DNA, HBeAg, anti-HBe and alanine aminotransferase (ALT) levels were serially monitored. The study groups were defined, using a hybridization assay, as patients with reductions in serum HBV-DNA below the detectable level (group I) or patients with persistently detectable serum HBV-DNA (group II) during the initial 6 months of lamivudine therapy. Results: The incidence of patients who had persistently detectable HBV-DNA was 7.7%. After the first year, the rates of viral breakthrough, HBeAg loss and serum ALT normalization of group I versus group II were 21% versus 63%, 38% versus 0%, and 71% versus 28%, respectively (P < 0.001). The login reduction of serum HBV-DNA at 6 months was -4.58 log(10) for group I and -1.97 log(10) for group II (P < 0.001, bDNA assay). There were no pretreatment lamivudine-resistant mutants in group II. Conclusion: Lamivudine had little effect on serum HBV-DNA suppression, viral breakthrough suppression and rate of HBeAg loss and ALT normalization in chronic hepatitis B patients with persistently detectable serum HBV-DNA during the initial 6 months of therapy. Early termination of lamivudine therapy is advocated for these patients. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Blackwell Publishing Inc. | - |
dc.title | Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/j.1440-1746.2007.04921.x | - |
dc.identifier.scopusid | 2-s2.0-34547652163 | - |
dc.identifier.wosid | 000248544200013 | - |
dc.identifier.bibliographicCitation | Journal of Gastroenterology and Hepatology, v.22, no.8, pp 1220 - 1225 | - |
dc.citation.title | Journal of Gastroenterology and Hepatology | - |
dc.citation.volume | 22 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1220 | - |
dc.citation.endPage | 1225 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | E-ANTIGEN SEROCONVERSION | - |
dc.subject.keywordPlus | TERM FOLLOW-UP | - |
dc.subject.keywordPlus | INTERFERON-ALFA | - |
dc.subject.keywordPlus | YMDD VARIANTS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | EMERGENCE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | chronic hepatitis 3 | - |
dc.subject.keywordAuthor | hepatitis B virus DNA | - |
dc.subject.keywordAuthor | lamivudine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.